Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legor­re­ta is one of the most in­flu­en­tial play­ers in bio­phar­ma you like­ly nev­er heard of.

Over the last 24 years, Legor­re­ta’s Roy­al­ty Phar­ma group has be­come, by its own reck­on­ing, the biggest buy­er of drug roy­al­ties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug fran­chis­es, spend­ing $18 bil­lion in the process — $2.2 bil­lion last year alone. And he’s be­come one of the best-paid ex­ecs in the in­dus­try, reap­ing $28 mil­lion from the cash flow last year while re­serv­ing 20% of the cash flow, less ex­pens­es, for him­self.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.